Anti ppka

The following reagents and materials were used: anti-ALDH1B1 (ref. sc-374090) was purchased from Santa Cruz; anti-PI16 (ref. PAS 31882) from Thermo; anti-P70 S6K beta (ref: ab184551) from Abcam; and anti-Bcl-xL (ref. 2764), anti-pAkt (Ser473) (ref. 4060), anti-Akt (ref. 4685), anti-pMEK1/2 (Ser217/221) (ref. 9154), anti-MEK1/2 (ref. 9126), anti-pERK1/2 (Thr202/Tyr204) (ref. 4370), anti-ERK1/2 (ref. 9102), anti-pPKA (Thr197) (ref. 5661), anti-PKA (ref. 4782), anti-pSEK1/MKK4 (Ser257/Thr261) (ref. 9156), anti-SEK1/MKK4 (ref. 9152), anti pSAPK/JNK (Thr183/Tyr185) (ref. 9255), anti pSAPK/JNK (ref. 9252S), anti pMKK3-6 (Thr183/Tyr185) (ref. 9231), anti MKK3 (ref. 5674), anti p-p38 MAPK (Thr180/Tyr182) (ref. 4511), anti p38 MAPK (ref. 9212) were purchased from Cell Signaling. Electrophoresis reagents were purchased from Biorad and trypsin from Promega.

Human gastric cancer cell lines, including BGC-823, MGC, SGC-790, HGC, and MKN-45 were purchased from the American Type Culture Collection in 2015. All cells were cultured in DMEM, supplemented with 10% fetal bovine serum, and were grown in a humidified atmosphere containing a 95% air, 5% CO2 mixture at 37°C. Anti-AM, anti-P-JNK, anti-JNK, anti-P-PKA, anti-PKA, and anti-LC3-II/I antibodies were obtained from Abcam Technology (Cambridge, MA). Anti-cleaved-caspase3, anti-caspase3, anti-P-AKT, anti-AKT, anti-Beclin, and anti-CRLR antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-GAPDH, anti-Bax, anti-Bcl2, anti-RAMP1, anti-RAMP2, and anti-RAMP3 antibodies were obtained from Cell Signaling Technology (Beverly, MA).